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916Prophylaxis with Sirolimus and
Tacrolimus ± Antithymocyte Globulin Reduces the
Risk of Acute Graft-versus-Host Disease without an
Overall Survival Benefit Following Allogeneic
Stem Cell Transplantation
Lindsay L. Rosenbeck,1,3 Patrick J. Kiel,1,3 Iftekhar Kalsekar,4 Craig Vargo,1 John Baute,3
Cheryl K. Sullivan,3 Lisa Wood,3 Sahar Abdelqader,3 Jennifer Schwartz,2,3
Shivani Srivastava,2,3 Rafat Abonour,2,3 Michael J. Robertson,2,3 Robert P. Nelson Jr.,2,3
Kenneth Cornetta,2,3 Christopher A. Fausel,2,3 Sherif S. Farag2,3Methotrexate (MTX) is a standard agent used in combination with calcineurin inhibitors for graft-versus-host
disease (GVHD) prophylaxis in patients undergoing allogeneic hematopoietic cell (HCT) transplantation. We
retrospectively compared the incidence of acute GVHD (aGVHD), transplant-related morbidity, and mortality
in patients given sirolimus/tacrolimus6 antithymocyte globulin (ATG) versus MTX/tacrolimus or cyclosporine
and allogeneic transplantation for hematologic malignancies. Between January 1, 2005, and April 30, 2009, 106
consecutive patients received peripheral blood HCT or bone marrow grafts after 1 of 6 myeloablative
conditioning regimens. The incidence of grade II-IV aGVHD was 18.6% in patients who received sirolimus/
tacrolimus compared to 48.9% who received MTX (P 5 .001). The incidence of grade III-IV aGVHD was 5%
and 17% (P 5 .045), respectively. There was no difference in overall survival (OS) between the groups
(P 5 .160). Chronic GVHD (cGVHD) occurred in 40.4% who received sirolimus and 41.9% receiving MTX
(P5 .89). The incidence of thrombotic microangiopathy or interstitial pneumonitis was not significantly differ-
ent between groups. The reduction in the risk of severe aGVHD was offset by an increased (20% versus 4%,
P5.015) incidence of andmortality from sinusoidal obstructive syndrome (SOS). Sirolimus/tacrolimus appears
to reduce the incidence of aGVHD after conventional allotransplantion compared to MTX-calcineurin
inhibitor prophylaxis; however, this did not improve survival.
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syndromeINTRODUCTION for GVHD prophylaxis [1,2]. Using this combination,Graft-versus-host disease (GVHD) remains 1 of
the most important complications of hematopoietic
cell transplantation (HCT). Currently, methotrexate
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/$36.00
6/j.bbmt.2010.09.017the incidence of grade II-IV GVHD ranges from 35%
to 50% with matched, related donors (MRD), and
approximately 40% to 70% after matched, unrelated
donor (MUD) transplants [3-5].
Sirolimus, the first inhibitor of the mammalian tar-
get of rapamycin (mTOR), binds to FK506 binding
protein 12 (FKBP12) to inhibit several biochemical
pathways that prevent progression of cells from S to
G1 phase and interferes with signal transduction that
mediates cytokine responses [6]. The unique mecha-
nisms of sirolimus permit the inhibition of T cell
proliferation rather than interleukin-2 production
[6,7]. Sirolimus also assists in expanding T-regulatory
cells influencing alloreactivity, whereas calcineurin
inhibitors are thought to negatively affect these cells [8].
Powell et al. [9] demonstrated that sirolimus in-
duced immunologic tolerance in cell cultures and after
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that sirolimus facilitates donor chimerism after trans-
plantation for nonmalignant disorders. Sirolimus
permitted the achievement of mixed-donor chimerism
and reversed the sickle cell phenotype following
nonmyeloablative allogeneic transplantation in 10
adult patients [10]. These data suggest that sirolimus
has the potential to induce immunologic tolerance
that may account for the decrease in the incidence of
acute GVHD (aGVHD) following allogeneic HCT
when used in combination with tacrolimus [9-11].
Additionally, sirolimus improves solid-organ allograft
survival while preserving renal function [12].
Cutler et al. [13] successfully utilized sirolimus and
tacrolimuswithoutMTX ina phase II trial of 83patients
undergoing HCT. The incidence of aGVHD was
20.5%, and the 30- and 100-day mortality rates were
0% and 4.8%, respectively. No difference was observed
betweenMRDandMUDtransplantswith respect to the
incidence of GVHD, transplant-related toxicity, and
relapse-free (RFS) or overall survival (OS).
Reports of sirolimus used with reduced-intensity
conditioning (RIC) regimens suggest the agent to be ef-
fective in preventing GVHD with an acceptable safety
profile [14-16]. The utilization of mTOR inhibitors
for antineoplastic effects has led to exploration of
their use for the treatment of lymphoma [15]. Patients
with lymphoma who received sirolimus for GVHD
prophylaxis experience a lower incidence of disease
progression and improved survival compared with
patientswhodid not receive sirolimus.The 100-day cu-
mulative incidence of grade II-IV aGVHDwas 14% in
the sirolimus group compared to 22% in the group not
receiving sirolimus.
Numerous complications following HCT include
drug and nondrug toxicities. Thrombotic microangi-
opathy (TMA) and interstitial pneumonitis (IP) are
severe adverse events following allogeneic stem cell
transplant and can be attributed to the transplant itself,
but also to calcineurin and mTOR inhibitors [17-19].
Sinusoidal obstructive syndrome (SOS) is a serious
liver complication following myeloablative therapy
after HCT, which has an occurrence rate of 5% to
15% [20]. Data suggest an increased risk of SOS
with sirolimus when used in GVHD prophylaxis
[21]. In this study, we report our experience using siro-
limus and tacrolimus for prophylaxis of GVHD since
adopting this regimen in January 2007, and compare
the incidence of aGVHD following this regimen rela-
tive to MTX/calcineurin-based immunosuppression.PATIENTS AND METHODS
Study Design and Patient Eligibility
This study was a retrospective analysis conducted
at Indiana University Simon Cancer Center (IUSCC),Indianapolis, Indiana. Data were collected from 106
consecutive patients between January 1, 2005 and April
30, 2009. The Indiana University-Purdue University
institutional review board approved this observational
study. Patients at our institution prior to January 1,
2007 primarily receivedMTXwith either cyclosporine
or tacrolimus for GVHD prophylaxis. After January 1,
2007, consecutive patients treated on standard-of-care
regimens were given sirolimus/tacrolimus for GVHD
prophylaxis, with antithymocyte globulin (ATG) also
administered to recipients of mismatched, related do-
nor or MUD transplants. However, some patients
were specifically enrolled on research protocols where
MTX-based regimens were mandated; and the deci-
sion to enroll was independent of knowledge of
GVHD prophylactic regimen. The primary endpoints
of the study were to compare the incidence of aGVHD
in the first 100 days following transplantation. Second-
ary endpoints included the incidence of chronic
GVHD (cGVHD), SOS, TMA, IP, and mortality.
Patients were included in the analysis if they were
aged 18 years of age or older, received a myeloablative
preparative regimen for transplantation for hemato-
logic malignancy, and had received either MTX plus
either cyclosporine or tacrolimus, or sirolimus/tacroli-
mus. All patients and recipients were matched at least
at HLA-A, -B, and -DRB1 (high-resolution typing);
those mismatched were mismatched at HLA-C and/
or -DQB1. Patients were excluded if they received
reduced-intensity regimens, haploidentical, syngeneic,
or umbilical cord donor cells, or had more than 2 prior
transplants. Transplantation risk was defined as ‘‘low’’
for patients with acute leukemia in first or subsequent
remission, or chronic myeloid leukemia in chronic
phase. All others were considered ‘‘high’’ risk.GVHD Prophylaxis
Patients received MTX, 15 mg/m2 on day 11 fol-
lowed by MTX, 10 mg/m2 on days 13, 16, and 111.
In combination with MTX, cyclosporine was adminis-
tered, 1.5 mg/kg intravenously (i.v.) every 12 hours be-
ginning on day21 with targeted serum concentrations
of 200 to 300 ng/mL. Tacrolimus 0.02 mg/kg/day, i.v.
by continuous infusion was started on day23, targeting
serum concentrations of 5 to 10 ng/mL. Sirolimus was
begunonday23,witha loadingdoseof12mgorally fol-
lowed by 4 mg once daily (starting on day22) to main-
tain a serum level of 5 to 15 ng/mL by microparticle
enzyme immunoassay. Tacrolimus was administered
to both groups similarly. Drug levels were monitored
at least 3 times per week during hospitalization; cyclo-
sporine and tacrolimus were changed to oral formula-
tions prior to discharge. In the absence of GVHD,
tapering of immunosuppression began on day 1100 as
tolerated, with a goal of stopping by day1180. Patients
who received unrelated or mismatched donor cells,
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ATG, 2.5 mg/kg i.v. on days 23, 22, and 21. Filgras-
tim, 5 mg/kg, subcutaneously (s.c.), was given daily start-
ing on day 0 until the absolute neutrophil count (ANC)
was .2000/mL for 2 days or 10,000/mL for 1 day. All
patients received acyclovir, fluconazole, and ciprofloxa-
cin for antimicrobial prophylaxis. After engraftment,
sulfamethoxazole/trimethoprim or pentamidine was
initiated for Pneumoncystis jiroveci prophylaxis. Cyto-
megalovirus (CMV) viral load was monitored weekly
and a preemptive therapy utilized for reactivation [22].
Acute GVHD and cGVHD were graded according to
previously published criteria [23,24], and biopsy was
required for confirmation of diagnosis.Statistical Analysis
Analysis was performed based on an intent-to-treat
basis. Baseline demographic and clinical characteristics
between the 2 study groups were compared using the
chi-square or Fisher exact test for categoric variables
and the Student t test orMann-WhitneyU test as appro-
priate. Data for the analysis were sealed on October 31,
2009, allowing aminimumof 6months follow-up for all
patients. The time to aGVHD and toOS between the 2
groups was estimated using Kaplan-Meier analysis [25]
and compared using the log-rank test [26]. Multivariate
analysis was performed to examine the impact of the
GVHD prophylactic regimen on risk of aGVHD and
survival. A stepwise (forward conditional) Cox-
proportional hazards model [27] was used. The model
included the following variables: type of prophylactic
regimen, transplant date (prior or after January 1,
2007) and disease risk. The remaining control variables
such as age, sex, HLA mismatch, type of donor (related
or unrelated), sex mismatch, underlying malignancy,
stem cell source (bonemarrow versus peripheral blood),
conditioning regimen, donor and recipientCMV status,
and ATG use were entered in the model in a stepwise
fashion. All the survival models were tested for the pro-
portionality hazards assumption. Univariate and multi-
variate logistic regression (forward conditional models
similar to the Cox proportional hazards models) were
used to assess the impact of the prophylactic regimen
on the incidence of SOS, TMA, and IP. All statistical
analyses were performed using SPSS 17.0 (SPSS, Inc.,
Chicago, IL) and STATA 9.0 (STATA Corp., College
Station, TX). Statistical significance was set at 0.05
(2 sided).RESULTS
Patient and Transplant Characteristics
Table 1 summarizes the baseline characteristics of
the 2 groups. Fifty-nine patients received sirolimus/
tacrolimus and 47 received MTX-based immunosup-pression.Of patients receivingMTX, 33 (70%) received
cyclosporine and 14 (30%), tacrolimus. The median
(range) ages for the sirolimus and MTX groups were
44 (21-59) and 39 (20-57) years, respectively (P 5
.069). Thirty-four (57%) in the sirolimus group and 19
(40%) patients in the MTX group received stem cells
from unrelated donors (P 5 .078). Eleven patients in
the tacrolimus/sirolimus group had unrelated donors
and mismatched at 1 locus (9 of 10). Two patients
were mismatched at 2 loci (8 of 10), 1 with an unrelated
donor and 1 a related donor. Of the patients with unre-
lated donors in the MTX group, 7 were mismatched
9 of 10, and 1 was an 8 of 10 mismatch. One patient
was a 5 of 6 HLAmismatch with a related donor. Other
baseline characteristics were similar between the groups
(Table 1) with the exception that the sirolimus group
had a higher proportion of patients with acute leukemia
(P 5 .007) and a greater fraction received ATG (P\
.001). The percentage of patients having high-risk
AMLwas similar between the 2 groups (P5 .873).Con-
ditioning regimens were classified as either radiation-
based (total-body irradiation [TBI]/cyclophosphamide
[Cy] and TBI/etoposide) or chemotherapy-based
(busulfan [Bu]/Cy, Bu/clofarabine, Bu/fludarabine, or
thiotepa/Cy). Mean tacrolimus and sirolimus levels
calculated from day 0 to day 135 were 8.8 ng/mL and
9.6 ng/mL, respectively.Acute GVHD
The incidence of grade II-IV aGVHD before day
1100 was 18.6% (11 of 59) in patients receiving
sirolimus/tacrolimus, compared to 48.9% (23 of 47)
receiving MTX (P 5 .001). The incidence of grade
III-IV aGVHD was 5.1% (3 of 59) and 17% (8 of
47) for the sirolimus and MTX groups, respectively
(P5 .045). As show in Figure 1, the risk of developing
aGVHD was significantly lower in patients who re-
ceived sirolimus and tacrolimus (P5 .002). Among pa-
tients who developed aGVHD by day1100, the mean
time to develop aGVHD was 90 days, compared to 70
days for those who received a MTX-based regimen
(P 5 .002). The results of multivariate analysis are
shown in Table 2. After controlling for other baseline
demographic, clinical, and treatment characteristics,
the hazard for aGVHD in patients using MTX-based
prophylaxis was 5.8 times higher than those given the
sirolimus/tacrolimus regimen (P 5 .002). The only
other significant variable affecting risk of aGVHD
was recipient CMV status hazard ratio (HR) 2.84
(95% confidence interval [CI], 1.28-6.29). Having an
unrelated donor and HLA mismatch also did not
appear to affect incidence or severity of GVHD.
Two of 12 with mismatched, unrelated donors receiv-
ing tacrolimus/sirolimus/ATG developed GVHD. In
theMTX group, 4 of the 8 withmismatched, unrelated
donors developed GVHD, 1 being grade 4.
Table 1. Baseline Characteristics
Sirolimus/
Tacrolimus MTX-Based
P Valuen 5 59 n 5 47
Median age, years (range) 44 (21-59) 39 (20-57) 0.069
Male sex, n (%) 28 (48) 25 (55) 0.441
Matched, unrelated donors, n (%) 34 (58) 19 (40) 0.078
HLA mismatched, n (%) 13 (22) 9 (19) 0.716
Sex mismatch, n (%) 29 (49) 23 (49) 0.982
Disease
Acute leukemia, n (%) 50 (85) 30 (64) 0.007
ALL 11 (19) 9 (19)
MDS 5 (8) 3 (6)
AML 34 (58) 18 (38)
Other, n (%) 9 (15) 17 (36)
CML/CMML 4 (7) 7 (15)
NHL 4 (7) 9 (19)
Myelofibrosis 1 (2) 1 (2)
High-risk leukemia 11 (18.6) 6 (12.8) 0.413
Stem cell source 0.261
Peripheral blood, n (%) 47 (80) 33 (70)
Bone marrow, n (%) 12 (20) 14 (30)
CMV status
Recipient seropositive, n (%) 35 (59) 27 (57) 0.846
Donor seropositive, n (%) 26 (44) 18 (38) 0.549
Conditioning regimen
Radiation-based 32 (54) 21(45) 0.328
TBI/Cy 21 (36) 16 (34)
TBI/Etoposide 11 (19) 5 (11)
Chemotherapy-based 27 (46) 26 (55)
Busulfan/Cy 0 24 (51)
Busulfan/clofarabine 14 (24) 0
Busulfan/fludarabine 8 (14) 2 (4)
Thiotepa/Cy 5 (9) 0
Received ATG, n (%) 28 (48) 1 (2) <0.001
HLA indicates human leukocyte antigen; AML, acute myeloid leukemia;
ALL, acute lymphoid leukemia; CML, chronic myeloid leukemia; CMML,
chronic myelomonocytic leukemia; NHL, non-Hodgkin lymphoma;
CMV, cytomegalovirus; TBI, total-body irradiation; Cy, cyclophosphamide;
ATG, antithymocyte globulin.
Figure 1. Risk of aGVHD by prophylactic regimen.
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Survival at days 130 and 1100 were similar be-
tween the sirolimus/tacrolimus group and MTX
group. At day130, 96.6% (57/59) of patients receiving
sirolimus and 97.9% (46 of 47) receiving MTX were
alive (P 5 .697). By day 1100, 79.9% (47 of 59) and
91.4% (43 of 47) of patients were living in each group,
respectively (P5 .091). There was no difference in OS
between the prophylactic regimens (log-rank, P 5
.160) (Figure 2A). As shown in Table 2 for multivari-
able analysis, no significant association was observed
between the GVHD prophylactic regimen and OS af-
ter adjusting for other variables. Patient age, HR 1.03
(95% CI, 1-1.06), and having an unrelated donor, HR
2.4 (95%CI, 1.34-4.33), were the only significant vari-
ables that affected survival. Similarly, as shown in
Figure 2B, no difference was observed between the 2
groups with respect to RFS (P 5 .13).
Table 3 shows the causes of death for patients in
the 2 groups. Of 12 with SOS in the sirolimus group,
8 died. Viral infections also accounted for a largernumber of deaths in the sirolimus group; these patients
all received ATG (5 versus 1 patient). Mortality be-
cause of GVHD was similar in both groups. OS was
not significantly impacted in those patients who
received busulfan-based conditioning regimens, P 5
.229. Additionally, ATG did not appear to influence
relapse rates as 29% (9 of 31) who relapsed who did
not receive ATG compared to 31% (9 of 29) of those
who did received ATG, relapsed.Chronic GVHD and Transplant-Related Toxicity
Of patients who lived 100 days posttransplant, 19
of 47 had cGVHD in the sirolimus group compared
to 18 of 43 in the MTX group (40.4% versus 41.9%,
P 5 .89). There was no significant difference in the
incidence of TMA (10.2% versus 4.3%, P 5 .296) or
IP (11.9% versus 14.9%, P 5 .647).
The incidence of SOSof the liver occurred in 20.3%
(12 of 59) who received sirolimus compared to 4.2% (2
of 47) in those who received MTX, P 5 .015. Patients
in the sirolimus group who developed SOS had a signif-
icantly higher mean trough sirolimus level during
the first 35 days posttransplant compared to those who
did not develop SOS (unpublished data). In brief, the
mean (6SD) blood sirolimus concentration levels
for patients who developed SOS was increased relative
to those who did not develop SOS, 10.5 ng/mL
(1.7 ng/mL) versus 8.7 ng/mL (1.8 ng/mL), P 5 .003.
In patients who developed SOS, the mean (6SD) blood
trough tacrolimus concentration levels were 9.2 ng/mL
(1.9 ng/mL) compared to 8.4 ng/mL (1.1 ng/mL) for
non-SOS patients, P5 .085.
Table 2. Cox-proportional Hazard Model for the Impact of Type of Prophylactic Regimen on Acute GVHD and Survival
Acute GVHD Overall Survival
Hazard Ratios
(95% Confidence Interval) P Value
Hazard Ratios
(95% Confidence Interval) P Value
Methotrexate as a prophylactic agent (reference: Sirolimus) 5.84 (1.96-17.4) 0.002 0.69 (0.23-2.14) 0.525
Transplant (day 0) prior to Jan 2007 0.5 (0.2-1.25) 0.14 1.4 (0.48-4.13) 0.54
High-risk leukemia 1.01 (0.36-2.8) 0.99 1.4 (0.64-2.95) 0.42
GVHD indicates graft-versus-host disease; MUD, matched, unrelated donor; CMV, cytomegalovirus.
The stepwise forward conditional models were additionally controlled for the following variables: age, sex, HLA mismatch, type of donor (related or
unrelated), sex mismatch, underlying malignancy, stem cell source (bone marrow versus peripheral blood), conditioning regimen, donor and recipient
CMV status, and ATG use.
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and busulfan (n 5 22), 4 developed SOS: 3 were fatal.
These 3 fatalities received Bu/fludarabine and the
other Bu/clofarabine. Of the patients receiving siroli-
mus and TBI/Cy (n 5 21), 7 developed SOS: 5 were
fatal. One of the 11 patients receiving TBI/etoposide
developed SOS that was nonfatal. Nonfatal SOS was
diagnosed in 2 patients in the MTX group; both had
received Bu/Cy. Overall, busulfan was part of the mye-
loablative conditioning regimen in 33% of patientsFigure 2. (A) OS. (B) RFS.who developed SOS and 38% of patients who did
not develop SOS (P 5 1).
Results of the multivariate logistic regression were
consistent with the univariate analysis and did not in-
dicate a significant impact of type of prophylactic reg-
imen on cGVHD and transplant-related toxicity (data
not shown).DISCUSSION
Although the goal of HCT is to eradicate the ma-
lignancy, transplant-related morbidity and mortality
present barriers to the overall success of the procedure.
Our analysis demonstrates a reduction in aGVHD for
patients who received sirolimus/tacrolimus compared
to MTX-based GVHD prophylaxis; patients who re-
ceived MTX-based prophylaxis were almost 6 times
more likely to develop aGVHD as those receiving
sirolimus.
A previous report observed rates of aGVHD
among MRD and MUD allogeneic transplants of
20% [13], similar to those observed in our study de-
spite a more heterogeneous population analyzed.
However, a recent pilot of tacrolimus/sirolimus
GVHD prophylaxis by Rodriguez et al. [28], demon-
strated a much higher incidence of grade II-IV
aGVHD (43%) and grade III-IV (19%). The reasons
for the apparently significant differences in incidence
of aGVHD observed between the Dana Farber Cancer
Institute (DFCI) and our study and those reported by
Rodriquez is not immediately clear, but may be relatedTable 3. Cause of Death
Sirolimus/Tacrolimus
n 5 41
MTX-based
n 5 25
Relapse 13 9
SOS 8 0
GVHD 3 2
Infection 8 8
Viral 5 1
Mold 3 3
Multisystem organ failure 1 2
SOS indicates sinusoidal obstructive syndrome; GVHD, graft-versus-
host disease.
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pression, and supportive measures that may not be
obvious in the reports.
Rabbit ATGwas given to those who received a mis-
matched related donor or MUD transplant, along with
sirolimus/tacrolimus. Rabbit ATG appears to reduce
cGVHD without impacting the incidence of aGVHD
in certain study populations at a dose of 7.5 mg/kg
[29-31]. Although ATG was not shown by multivariate
analysis to impact either aGVHD or cGVHD, our
findings do not entirely exclude a possible anti-GVHD
effect of ATG, as 5 of 29 (17%) of patients who received
ATG developed aGVHD, compared to 29 of 77
(37.7%) of those who did not (P5 .061).We also exclu-
sively used high-resolutionHLA-typing, whereas previ-
ously published trials with ATG utilized a combination
of serologic and high-resolution typing, potentially
influencing the effect of rabbit ATG on the incidence
of GVHD [31]. SOS occurred in 20% of patients who
received sirolimus/tacrolimus, of which 8 deaths were
attributed. This incidence is higher than what was
previously reported (6%-10%) by the DFCI [13,21].
Sirolimus reduces endothelial cell proliferation,
vascular smooth muscle and neointima formation, and
vascular smooth muscle cell integrity. It also induces
endothelial progenitor cell death [32-34]. Cutler et al.
[21] found an 8-fold increase in SOS when sirolimus
was given with a Bu conditioning regimen. It is notable
that in our experience, although some patients devel-
opedSOSand receivedBu, others did not. It is unknown
whether the order of administration of TBI and cyclo-
phosphamide influences potential drug interactions
and adverse events such as SOS. The administration of
cyclophosphamide following TBI may have unknown
clinical outcomes with regard to sirolimus and tacroli-
mus drug metabolism interactions because of the
proximity of the drugs being coadministered.
There are many competing causes of death follow-
ing allogeneic HCT including relapse, regimen-related
toxicity, and infection. In this study, the significant
reduction in the incidence of severe aGVHD did not
translate to a survival benefit for patients treated with
sirolimus and tacrolimus. The benefit in reduction of
aGVHD was offset by a higher morality from SOS
and viral infections. Sirolimus has not been reported
to increase the risk of viral infection, and it is likely
that the higher mortality from viral infections observed
may have been related to the confounding effect of
ATG used at a dose of 7.5 mg/kg in the group [31].
Five of the 6 viral-related fatalities were in patients
who receivedATG.The rates of relapsewere not differ-
ent between the 2 groups, suggesting that differences in
OS are a result of regimen-related toxicity.
In conclusion, the combination of sirolimus/tacro-
limus resulted in a significant decrease in the incidence
and the severity of aGVHD compared to MTX-based
immunosuppression. OS was not improved, primarilybecause of an unexpected increased incidence of SOS
with TBI/Cy and Bu-based regimens, and infectious
complications associated with the use of ATG. Reduc-
tion of these complications through the use of other
regimens and avoidance (or lower doses) of ATG
might result in an improved outcome. The results of
an ongoing Phase III trial comparing sirolimus/
tacrolimus to standard GVHD-preventive regimens
may clarify the role of the combination in conventional
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